Details

Autor(en) / Beteiligte

• Stevenson, Jennifer
• Poker, Rachel
• Schoss, Johanna
• Campbell, Michael
• Everitt, Claire
• Holly, Brian
• Stones, Nicholas
• Pettis, Ronald J.
• Sanchez-Felix, Manuel

Titel

Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design

Ist Teil von

• Advanced drug delivery reviews, 2024-04, Vol.209, p.115322-115322, Article 115322

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• [Display omitted] •Patient preferences and perspectives on injectable drug delivery vary widely.•The many factors contributing to these differences are not well understood.•The SC Consortium aims to advance patient-centric subcutaneous drug delivery.•Pharma/biotech industry survey results of patient experience parameters are provided.•The current knowledge of factors impacting patient preference are discussed.•Gaps in knowledge are identified and expert insights to fill gaps are provided. Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient’s treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.